MET and neoplasm: Aberrant cMet expression or constitutive activation of the cMet signaling pathway due to amplification, overexpression of its ligand HGF, and mutation in MET is seen in many human tumor types and is the rationale for developing cMet‐targeting therapeutics (Gherardi et al., 2012).